eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/24/2017 | Series C | $39.1MM | $xx.xx | $197.73MM | Pfizer Venture Investments, Alexandria Venture Investments, U.S. Venture Partners, Abingworth, Novartis Venture Fund, SR One, The Column Group, Altitude Life Science Ventures, Sectoral Asset Management, Abbvie Biotech Ventures, BioMed Ventures, Astellas Ventures | |
Price per Share
$xx.xx
Shares Outstanding
76,070,076
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Pfizer Venture Investments, Alexandria Venture Investments, U.S. Venture Partners, Abingworth, Novartis Venture Fund, SR One, The Column Group, Altitude Life Science Ventures, Sectoral Asset Management, Abbvie Biotech Ventures, BioMed Ventures, Astellas Ventures
|
||||||
12/22/2015 | Series B | $56MM | $xx.xx | $141.22MM | Altitude Life Science Ventures, AbbVie Biotech Ventures, BioMed Ventures, Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Ventures, Osage University Partners, Mission Bay Capital | |
Price per Share
$xx.xx
Shares Outstanding
114,646,041
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Altitude Life Science Ventures, AbbVie Biotech Ventures, BioMed Ventures, Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Ventures, Osage University Partners, Mission Bay Capital
|
||||||
05/20/2013 | Series A | $56.98MM | $xx.xx | $67.04MM | SR One, Novartis Venture Funds, Astellas Venture Management, Abingworth, Osage University Partners, U.S. Venture Partners, Mission Bay Capital | |
Price per Share
$xx.xx
Shares Outstanding
145,560,097
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
11.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
SR One, Novartis Venture Funds, Astellas Venture Management, Abingworth, Osage University Partners, U.S. Venture Partners, Mission Bay Capital
|